Krebs, Tumor-Mikromilieu, Metabolismus

Ausgewählte Publikationen

  • Dahlem C, Abuhaliema A, Kessler SM, Kröhler T, Zoller BGE, Chanda S, Wu Y, Both S, Müller F, Lepikhov K, Kirsch SH, Laggai S, Müller R, Empting M, Kiemer AK. 2022. First small-molecule inhibitors targeting the RNA-binding protein IGF2BP2/IMP2 for cancer therapy. ACS Chem Biol 17:361-375
     
  • Dahlem C, Chanda S, Hemmer J, Schymik HS, Kohlstedt M, Wittmann C, Kiemer AK. 2022. Characterization of anti-cancer activities of violacein: Actions on tumor cells and the tumor microenvironment. Front Oncol 12:872223
     
  • Hoppstädter J, Dembek A, Höring M, Liebisch G, Dahlem C, Sultan A, Wirth N, Al-Fityan S, Diesel B, Gasparoni G, Walter J, Helms V, Huwer H, Simon M, Schulz MH, Kiemer AK. 2021. Dysregulation of cholesterol homeostasis in human lung cancer tissue and tumor-associated macrophages. EBioMedicine 72:103578
     
  • Dahlem C, Siow WX, Lopatniuk M, Fai Tse WK, Kessler SM, Kirsch SH, Hoppstädter J, Vollmar, AM, Müller R, Luzhetskyy A, Bartel K, Kiemer AK. 2020. Thioholgamide A, a new anti-proliferative anti-tumor agent, modulates macrophage polarization and metabolism. Cancers 12:1288
     
  • Messner M, Schmitt S, Ardelt MA, Fröhlich T, Müller M, Pein H, Huber-Cantonati P, Ortler C, Koenig LM, Zobel L, Koeberle A, Arnold GJ, Rothenfusser S, Kiemer AK, Gerbes AL, Zischka, Vollmar AM, Pachmayr J. 2020. Metabolic implication of tigecycline as an efficacious second-line treatment for sorafenib-resistant hepatocellular carcinoma, FASEB J 34:11860–11882
     
  • Kessler SM, Hosseini K, Hussein UK, Kim KM, List M, Schultheiss CS, Schulz MH, Laggai S, Jang KY, Kiemer AK. 2019. Hepatocellular carcinoma and nuclear paraspeckles: induction in chemoresistance and prediction for poor survival. Cell Physiol Biochem 52:787-801
     
  • Kröhler T, Kessler SM, Hosseini K, List M, Barghash A, Patial S, Laggai S, Gemperlein K, Haybäck J, Müller R, Helms V, Schulz MH, Hoppstädter J, Blackshear PJ, Kiemer AK. 2019. The mRNA-binding protein TTP in hepatocarcinogenesis and hepatocellular carcinoma. Cancers 11:1754
     
  • Czepukojc B, Abuhaliema A, Barghash A, Tierling S, Simon Y, Körbel C, Cadenas C, van Hul N, Sachinidis A, Hengstler JG, Helms V, Laschke MW, Walter J, Haybaeck J, Leclercq I, Kiemer AK, Kessler SM. 2019. IGF2 mRNA binding protein 2 transgenic mice are more prone to develop a ductular reaction and to progress towards cirrhosis. Front Med 6:179
     
  • Levada K, Guldiken N, Vella G, James LP, Haybaeck J, Kessler SM, Kiemer AK, Ott T, Trautwein C, Strnad P. 2018. Hsp72 overexpression protects from liver injury via attenuation of hepatocellular death, oxidative stress and JNK-signaling. J Hepatol 68:966-1005
     
  • Schultheiss CS, Laggei S, Czepukojc B, Hussein UK, List M, Barghash A, Tierling S, Hosseini K, Golob-Schwarzl N, Pokorny J, Hachenthal N, Schulz M, Helms V, Walter J, Zimmer V, Lammert F, Bohle RM, Dandolo L, Haybaeck J, Kiemer AK, Kessler SM. 2017. The long non-conding RNA H19 suppresses carcinogenesis and chemoresistance in hepatocellular carcinoma. Cell Stress 1:37-57
     
  • Kessler SM, Lederer E, Laggai S, Golob-Schwarzl N, Hosseini K, Petzold J, Schweiger C, Reihs R, Keil M, Hoffmann J, Christian Mayr, Kiesslich T, Pilcher M, Kim KS, Rhee H, Park YN, Lax S, Obrist P, Kiemer AK, Haybaeck J. 2017. IMP2/IGF2BP2 expression, but not IMP1 and IMP3, predicts poor outcome in patients and high tumor growth rate in xenograft models of gallbladder cancer. Oncotarget 8:89736-89745
     
  • Kessler SM, Laggai S, van Wonterghem E, Gemperlein K, Müller R, Haybaeck J, Vandenbroucke RE, Ogris M, Libert C, Kiemer AK. 2016. Transient hepatic overexpression of IGF2 induces free cholesterol and lipid droplet formation. Front Physiol 7:147
     
  • Kessler SM, Laggai S, Barghash A, Schultheiss CS, Lederer E, Artl M, Helms V, Haybaeck J, Kiemer AK. 2015. IMP2/p62 induces genomic instability and a stem-like HCC phenotype. Cell Death Dis 6:e1894
     
  • Simon Y, Kessler SM, Bohle RM, Haybaeck J, Kiemer AK. 2014. The insulin-like growth factor 2 (IGF2) mRNA binding protein p62/IMP2-2/IGF2BP2-2 as a promoter of NAFLD and HCC? Gut 63:861-863
     
  • Kessler SM, Laggai S, Barghash A, Helms V, Kiemer AK. 2014. Lipid metabolism signatures in NASH-associated HCC - Letter. Cancer Res 74:2903-2904
     
  • Laggai S, Kessler SM, Boettcher S, Lebrun V, Gemperlein K, Lederer E, Leclercq IA, Mueller R, Hartmann RW, Haybaeck J, Kiemer AK. 2014. The IGF2 mRNA binding protein p62/IGF2BP2-2 induces fatty acid elongation as a critical feature of steatosis. J Lipid Res 55:1087-1097
     
  • Tybl E, Shi F-D, Kessler SM, Tierling S, Walter J, Bohle RM, Wieland S, Zhang J, Tan EM, Kiemer AK. 2011. Overexpression of the Igf2-mRNA binding protein p62 in transgenic mice induces a steatotic phenotype. J Hepatol 54:994-1001